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Abstract
Background
The outbreak of coronavirus disease, 2019 (COVID-19), which started from Wuhan, China,
in late 2019, have spread worldwide. A total of 5,91,971 cases and 2,70,90 deaths were reg-
istered till 28th March, 2020. We aimed to predict the impact of duration of exposure to
COVID-19 on the mortality rates increment.
Methods
In the present study, data on COVID-19 infected top seven countries viz., Germany, China,
France, United Kingdom, Iran, Italy and Spain, and World as a whole, were used for model-
ing. The analytical procedure of generalized linear model followed by Gompertz link function
was used to predict the impact lethal duration of exposure on the mortality rates.
Findings
Of the selected countries and World as whole, the projection based on 21st March, 2020
cases, suggest that a total (95% Cl) of 76 (65–151) days of exposure in Germany, mortality
rate will increase by 5 times to 1%. In countries like France and United Kingdom, our projec-
tion suggests that additional exposure of 48 days and 7 days, respectively, will raise the
mortality rates to10%. Regarding Iran, Italy and Spain, mortality rate will rise to 10% with an
additional 3–10 days of exposure. World’s mortality rates will continue increase by 1% in
every three weeks. The predicted interval of lethal duration corresponding to each country
has found to be consistent with the mortality rates observed on 28th March, 2020.
Conclusion
The prediction of lethal duration was found to have apparently effective in predicting mortal-
ity, and shows concordance with prevailing rates. In absence of any vaccine against
COVID-19 infection, the present study adds information about the quantum of the severity
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and time elapsed to death will help the Government to take necessary and appropriate
steps to control this pandemic.
1. Introduction
There are mainly three epidemics, which arisen with infections related to emerging coronavi-
ruses in last two decades, which are namely Severe Acute Respiratory Syndrome (SARS)and
the Middle East Respiratory Syndrome (MERS) and coronavirus disease-19 (COVID-19). It is
a respiratory syndrome related with the coronavirus that was first identified in Hubei Prov-
ince, PRC, in late 2019 and have spread globally, with the World Health Organization (WHO)
declared it a pandemic on 11 March 2020. Till 21st, March, 2020, this outbreak has affected
approximately300,000 people across the globe. Coronavirus is basically a zoonotic virus [1],
which is commonly found in camel, rat, bat and cattle. In previously known strains of Corona-
virus, viz., MERS-Cov and SARS-Cov [1, 2], it was rarely found that an animal coronavirus
infected human beings and through which it spreads to community. But, the infectious nature
of the virus to human being was firstly observed when its new strain, COVID-19infected peo-
ple were admitted to hospitals with similar problems of pneumonia with an unknown etiology
[3]. The chronicity and fatality of COVID-19 can be visualized from the fact that it is spreading
among humans and affects respiratory system, which causes severe respiratory diseases and
leads to death [4–6]. The threat due to COVID-19 can be seen from the fact that due to
increase and spread of its related cases and deaths, WHO on 11th of February, 2020 declared
the current time as a global public health emergency situation [7]. According to Centre for
Disease Control and Prevention (CDC), COVID-19 is also acting as a betacoronavirus like its
earlier strains of MERS-Cov and SARS-Cov, which were originated from bats [4].
The spreading kinetics of COVID-19 can be framed through cases found in China. Initially,
during 18-29th December, 2019, due to COVID-19 there were only 5 confirmed cases reported
and among them only single death occurred. The infected cases on 25th January 2020 were
increased to 1975,out of which 56 were deceased, and the count raised to 7734 with 90 deaths
till 30thJanuary, 2020 and spread to globally with fatality rate of 2.2% approximately [8].
According to WHO report, Italy is the worst hit with 9136 deaths, following Spain 4858 and
China a 3301 on 28th, March, 2020. Other mostly affected list of countries includes Germany,
Iran, France and the United Kingdom- where Prime Minister Mr. Boris Johnson has been
tested positive.
The most common pathological symptom observed among COVID-19 [4] infected individ-
ual is that the virus damages the alveolar, which leads to a respiratory failure and as normal
like flu, fever, cold, cough and shortness of breath, along with them the other severe symptoms
observed are sputum production, haemoptysis, lymphophenia and pneumonia, in some cases
increasing dyspnea and hypoxemia in the upper lobe of the lung were also observed. The silent
feature of COVID-19 is its associated symptoms that they will appear during incubation period
of 2–14 days [4]. COVID-19 can infect individuals of all ages and genders and can spread easily
from one person to another, but the likelihood of getting infected is higher among older popu-
lation, on various medical conditions, such as, diabetes, cardiovascular diseases, hypertension,
cancer and chronic respiratory diseases [9, 10]. Severe illness due to the COVID-19 leads to
death (mortality rate of 3% approximately) [10].
In the genomic sequence analysis, the COVID-19 has found to similar (82% of SARS-Cov
and 50% of MERS-Cov) [4] to earlier coronaviruses, which indicates mammals are more likely
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link between COVID-19 and humans [4]. The mode of transmission of COVID-19 from the
infected individual to another person or community is through individual’s droplets spread
while coughing and sneezing [4]. As of now, no vaccine or anti-viral drugs is available against
COVID-19 infection for potential therapy. Therefore, precautions, self-sanitization and isola-
tion, and practicing social distancing are only alternatives measures that are recommended to
control the current outbreak. In order to minimize the transmission and spreading of
COVID-19, ‘community-wide containment’ [11] is also required to be implemented on proper
time.
Majority of the recent investigations discussed in recent literatures were emphasized to pro-
vide a basis to understand the etiological, genetically and geographical aspects in association
with COVID-19 virus. As this is an ongoing issue and there is no research available on the
measurement of the severity of COVID-19 and time elapsed to death. Intensity of death may
vary due to demographic, socioeconomic, life-style factors and social norms. It is thus impor-
tant to know the risk factors of propensity of deaths due to deadly COVID-19. Based on the
available information, long period of exposure and systematic increase in number of cases are
also increasing its associated deaths. Thus the study aims to examine it here to add knowledge
in the exiting literature.
To study the COVID-19 virus spreading and fatal kinetics, it is assumed that individuals of
each country have their own tolerance, beyond which they start dying due to lethal characteris-
tics of the virus. The total number of deaths occurred due to COVID-19 after a particular dura-
tion of exposure may considered as a binomial random variable with known number of its
infected cases, but having unknown probability of death occurrence on that day, say π. If π can
be estimated by using the available information about the infection due to COVID-19 virus,
then one can use this estimate to derive the duration of infection that is estimated to cause π
proportion of death among infected individuals.
1.1 Objective
The objective of the present study is to suggest an effective and efficient model that captures
the predicted duration of exposure to COVID-19 and its impact on the mortality rates, π,
increment. And to evaluate the choronicity of COVID-19 in different countries, who are in
critical state by using the kinetics of time to death and define lethal duration for death
occurrence.
2. Methods
2.1 Data description
The data was initially accessed on 21th March 2020from the website of Our World in Data
(https://ourworldindata.org/coronavirus-source-data), which presented data from reliable
sources of WHO and European Centre for Disease Prevention and Control (ECDC), for
modeling purpose and again accessed on 28th March 2020 for validation of suggested method-
ology. This dataset organizes epidemiological aspects of incidence and mortality due to
COVID-19, as reported by public health authorities worldwide. For the present work, we have
considered the date-wise infected and death cases due to COVID-19of seven countries viz.,
Italy, Spain, China, Iran, France, United Kingdom and Germany, where highest number of
deaths have been reported, and World as a whole. Here, the first date of reporting of COVID-
19 case, corresponding to each selected country, was considered as the starting day. For the
prediction of lethal duration to attain a particular mortality rate, country’s or World’s informa-
tion after the 10th day of reporting was used. Based on mortality rates reported by each coun-
try and World on 21st March 2020, countries are classified into three categories, viz., Category
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I for countries whose mortality rates are less than 2%, Category II for countries whose mortal-
ity rates lies between 2–5% and Category III for countries where mortality rates reached more
than 5%. Based on the mortality rates, Germany belongs to Category I, China, France, United
Kingdom fall under Category II, and Iran, Italy and Spain included in category III. As per cate-
gories, the predicted mortality rates were also grouped into three classes, Class 1 of mortality
rates 1–5% (with 1% increment), Class 2 of 6–10% mortality rates (with 1% increment) and
Class 3 of 20–50% mortality rates (with 10% increment).
Let π denotes the mortality rates due to infection in the population after specific duration of
exposure and LDπ symbolizes the ‘lethal duration’ for severity due to COVID-19 in a popula-
tion, which is estimated to cause π proportion of death among infected individuals.Here, we
have tried to estimate and examine chronicity due to lethal duration of exposure, LDπ, and
severity due to COVID-19 virus, by using the available information of total number of cases
and deaths till date. The model considered for the present analysis is based on the basic
assumptions that (a) mortality rate is a function of duration of exposure to the infection (b)
mortality rates across the countries is independent. The methodological aspect of LDπ estima-
tion is done using Gompertz link function and its related 95% confidence interval is discussed
in Appendix section. The analysis was performed using SAS software, version 9.4 (SAS Insti-
tute Inc, Cary, North Carolina).
3. Results
Tables 1 and 3 presented the summary of total number of cases and deaths occurred due to
COVID-19, and duration of exposure, till 21st and 28th March 2020, respectively, along with
that the observed mortality rate in different countries and World as a whole, and classification
of these probabilities in different categories. Majority of the COVID-19 infected cases found as
of 21st March, 2020 were from China (81416) followed by Italy (47021) then Spain (19980),
and in terms of number of deaths occurred, Italy was on top followed by China and Iran. On
observing the number of cases and deaths occurred due to COVID-19 as of 28th March, 2020
majority were from Italy (86498) followed by China (82213) then Spain (64059), and in the
similar order of number deaths reported. Table 2 presented the predicted lethal duration, LD^
p
(in days of exposure) with 95% confidence interval (CI), for death occurrence in different
countries due to COVID-19 for the given mortality rate (π).The previous Class 1 and 2 of Cate-
gory II and III were showing the pattern of that transition. The visualization of the predicted
lethal duration (days) based on the classes of mortality rates (probability), which is expected to
be followed by each selected country and world as a whole based on their categories and with
the 95% CI were depicted in Figs 1 and 2–4, respectively.
Table 1. Duration of exposure and mortality rates in different countries due to COVID-19 on 21st March, 2020.
Country Total Cases Total Deaths Duration of exposure (21st March, 2020) Mortality rate π Category#
Germany 18323 45 54 0.002 I
China 81416 3261 81 0.040 II
France 12612 450 57 0.036 II
United Kingdom 3983 177 51 0.044 II
World 271364 11252 81 0.041 II
Iran 19644 1433 31 0.073 III
Italy 47021 4032 51 0.086 III
Spain 19980 1002 50 0.050 III
# Category I if π� 2%; Category II if π (2–5)%; Category III if π> 5%;
https://doi.org/10.1371/journal.pone.0233074.t001
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4. Discussion
From an extensive reporting of data on COVID-19 from different regions of the world, 75% of
COVID-19 infection cases and 92% of deaths related to COVID-19 infections were registered
in seven countries (Table 1). The situation of Italy was seems to be very critical due to increas-
ing numbers of COVID-19 infected cases and its associated deaths in 51 days. But, in terms of
mortality rates with respect to duration, Iran reached to 7.3% only in 31 days, whereas Italy
took 51 days to reach to 8.6%, which is of serious concern. The chronicity and infectious
nature of COVID-19 can be seen from the fact that within a span of seven days (50–57) the
mortality rates varies from 2–9% as 2% (Germany), 3.6% (France), 4.4% (United Kingdom),
5% (Spain) and 8.6% (Italy). In Germany, where 0.2% mortality rate has reported in 54 days
and belongs to Category I, the forecast presented in Table 2 and depicted in Fig 1, suggest that
within a duration of 76 days with 95% CI (65–151) will raise to 1%, thereafter will require on
Table 3. Duration of exposure and mortality rates in different countries due to COVID-19 on 28th March, 2020.
Country Total Cases Total Deaths Duration of exposure (28th March, 2020) Mortality rate π Category#
Germany 48582 325 61 0.007 I
China 82213 3301 89 0.040 II
World 591971 27090 89 0.046 II
France 32964 1995 64 0.061 III
Iran 32332 2378 38 0.074 III
Italy 86498 9136 58 0.106 III
Spain 64059 4858 57 0.076 III
United Kingdom 14543 759 58 0.052 III
# Category I if π� 2%; Category II if π (2–5)%; Category III if π> 5%;
https://doi.org/10.1371/journal.pone.0233074.t003
Table 2. Predicted lethal duration, LD^
p
ðtÞ(in days), in different countries due to COVID-19 for the given probability of death (π).
Class Probability (π) Predicted lethal duration, LD^
p
exposure, for death occurrence in countries� (in days) with 95% CI
Category I Category II Category III
Germany China France UK World Iran Italy Spain
1 0.01 76(65–151) 15(13–17) 33(9–40) 39(37–41) 15(13–16) 10(9–11) 18(15–20) 34(32–35)
0.02 91(42–248) 33(31–35) 46(62–50) 44(43–45) 34(32–35) 15(14–16) 25(23–27) 40(39–41)
0.03 101(77–332) 53(51–55) 57(54–67) 47(46–48) 55(54–56) 19(18–20) 30(28–32) 44(43–45)
0.04 109(81–410) 74(72–76) 65(60–108) 50(49–51) 78(76–80) 22(21–23) 34(32–36) 47(46–48)
0.05 116(84–482) 96(92–101) 73(64–158) 52(51–53) 102(99–107) 25(24–26) 38(37–40) 50(48–51)
2 0.06 119(112–127) 80(67–216) 53(52–55) 128(121–136) 28(27–29) 42(41–43) 52(51–53)
0.07 143(132–156) 87(73–284) 55(53–57) 155(145–166) 30(29–31) 45(44–46) 54(53–55)
0.08 167(153–186) 93(73–358) 56(54–58) 183(169–199) 33(32–34) 48(46–49) 56(55–58)
0.09 193(174–217) 99(77–441) 57(55–60) 211(194–233) 35(34–37) 51(50–52) 58(56–60)
0.10 218(196–249) 105(79–532) 58(56–62) 241(220–269) 37(36–39) 54(52–56) 59(58–61)
3 0.20 56(53–60) 76(72–82) 71(67–75)
0.30 73(68–79) 95(88–105) 79(74–86)
0.40 88(81–97) 113(102–128) 87(81–95)
0.50 104(95–116) 130(116–151) 93(86–103)
P value 0.0021 <0.0001 0.0042 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
� Selected countries are classified into different categories based on their death occurrence probability, π(.) on 21st March, 2019
https://doi.org/10.1371/journal.pone.0233074.t002
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an average an additional 15 days to reach to 2% deaths and if same trend follows, an additional
25 days will raise the mortality rate to 5%. Here, lower limit of the 95% confidence interval, for
Fig 1. Pattern of lethal duration of exposure to COVID-19due to probability of deaths in different categories of countries.
https://doi.org/10.1371/journal.pone.0233074.g001
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example, in case of Germany was 65 days, is indicating that if situation persists and remains
uncontrolled even after the lockdown or social distancing, the mortality rate will increase to
1% before the scheduled pattern and the upper limit, says, for example 151 days, shows the
effectiveness of initiatives towards controlling the situation. This duration found is statistically
associated with predicted mortality rate (p-value: 0.0021), which means that an increase in
lethal duration increases the predicted mortality rate [12, 13]. To validate the prediction and
performance of the model, we used the 28th March, 2020, with reference to Germany, as pre-
dicted, within 7 days, i.e., in 61 days of exposure, the mortality rate increased from 0.2% to
0.7%.
In case of Categories II countries, viz., France and United Kingdom, where deaths reported
as 3.6% and 4.4%, respectively, the forecast in Table 2 and Fig 2, suggest that the rates will
increase to 6% in lethal duration of exposure of 80(67–216) days in France and 53(52–55) days
in United Kingdom. The durations was significantly associated with predicted probabilities of
deaths and found to be statistically significant for France and United Kingdom; p-value:
0.0042 and<0.0001, respectively. Obtained intervals (Table 2) have found to be consistent
with the death rates observed in Table 3 on 28th March, 2020for France as 6% on 64th day and
United Kingdom as 5.4% on 58th day.
Category III countries, viz., Iran, Italy and Spain, mortality rates on 21st March, 2020
were, 7.3%, 8.6% and 5%, respectively. The projected lethal duration of exposure for raising
or mortality rates to 10%, as presented in Table 2 and Fig 3, in these counties shown that
Iran will take on an average of 37(36–39) days; Italy will take 54(52–56) days and Spain will
take 59(58–61) days, which is quite close to the mortality rates of Table 3 observed mortality
Fig 2. Inverse predicted probabilities of total deaths in Germany of Category I having Class 1 (0.01–0.05) mortality rates.
https://doi.org/10.1371/journal.pone.0233074.g002
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rates on 28th March, 2020, as Iran 7.4% on 38 days, Italy 10.6% on 58th day, and Spain 7.6%
on 57th day. The duration was significantly associated with predicted mortality rates in
these countries and found to have similar trend as seems in countries from category I and
category II (Table 2).
5. Conclusion
The projection of lethal duration of exposure to COVID-19 for different countries, where
comparatively higher number of infected cases and deaths were reported, is found to be very
realistic and effective to predict the mortality rates and suggest higher chances of increase in
rates. The present study is adding information about the quantum of the severity of COVID-
19 and time elapsed to death that can occur based on the current trend, which will help in
planning strategies required to be implemented in time. The obtained estimates of lethal dura-
tion of exposure give an indication of the casualty rates across the spectrum of COVID-19 dis-
ease and would eventually help to implement appropriate strategies to tackle this pandemic by
taking necessary and appropriate steps such as precautions, self-sanitization and isolation, and
by practicing social distancing.
Fig 3. Inverse predicted probabilities of total deaths in counties, China, France, United Kingdom (UK) and World as a whole of Category II having Class 2 (0.06–
0.1) mortality rates.
https://doi.org/10.1371/journal.pone.0233074.g003
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